Suppr超能文献

微小RNA-371-373簇与甲基化组分析表明,生殖细胞肿瘤中出现的一部分“体细胞型”恶性肿瘤可能起源于卵黄囊瘤成分。

MicroRNA-371-373 cluster and methylome analysis suggests that a subset of 'somatic-type' malignancies arising in germ cell tumors may originate in yolk sac tumor components.

作者信息

Lobo João, Tavares Nuno Tiago, Fonseca Diana, Jerónimo Carmen, Henrique Rui, Wyvekens Nicolas, Yang Yiying, Snuderl Matija, Maclean Fiona, Gordetsky Jennifer, Fletcher Christopher Dm, Hirsch Michelle S, Hornick Jason L, Idrees Muhammad T, Collins Katrina, Warmke Laura, Ulbright Thomas M, Acosta Andres M

机构信息

Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC), Porto, Portugal.

Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (P.CCC) & CI-IPOP@RISE (Health Research Network), Porto, Portugal.

出版信息

J Pathol. 2025 Jun;266(2):160-176. doi: 10.1002/path.6412. Epub 2025 Mar 28.

Abstract

Somatic-type malignancies (SMs) arising in germ cell tumors (GCTs) are aggressive neoplasms resistant to systemic treatment. Most are diagnosed in metastatic sites after chemotherapy; however, they have also been well-documented in primary testicular GCTs. Historically, SMs were thought to originate in components of teratoma that acquire molecular alterations equivalent to those that characterize their true somatic counterparts. However, recent studies have shown that SMs typically lack the hallmark molecular alterations seen in similar somatic tumors. Additionally, clinicopathologic and molecular data suggest that a subset may derive from yolk sac tumor (YST) rather than teratoma. In this study, we evaluated the relationship between conventional histological types of GCTs and SMs by comparing expression of microRNA (miR)-371-373 and genomic methylation profiles. A total of 96 samples (including multiple paired conventional GCT-SM samples from individual tumors) were assessed for miR-371-373 expression by RT-qPCR and genomic DNA methylation using a clinically validated assay. Expression of miR-371-373 was higher in conventional GCTs than in SMs (considered as a single category encompassing all histological subtypes). However, miR-371-373 expression was heterogeneous among SMs, with significantly higher levels in sarcomatoid YST (SYST) and glandular neoplasms than in other SMs. Genomic DNA methylation analysis showed that SMs (considered as a single category) did not form a distinct cluster. Instead, they grouped into multiple clusters that did not show perfect correspondence with histology and often included conventional GCTs. Genome-wide methylation assessment showed a higher abundance of hypermethylated regions in SMs than in conventional GCTs. Analysis of paired conventional GCT and 'somatic-type' components that did not meet size criteria for SMs dissected from individual tumors demonstrated separation according to histology, suggesting that epigenetic processes play a role in the transition from conventional GCT to 'somatic-type' phenotypes. Gene-level and pathway-level analyses identified MAPK/RAS signaling, mitosis/proliferation, differentiation towards neural tissue/neuroectoderm, epithelial-to-mesenchymal transition, and DNA repair as key differentially regulated processes in components with somatic-type histology, suggesting mechanisms of progression from conventional to 'somatic' phenotypes in GCT. These results support the hypothesis that a subset of SMs derive from YST and suggest that some subtypes (such as SYST) may represent 'intermediate' phenotypes. Additionally, analysis of differentially methylated promoter regions in SM identified genes and biologic processess that may underlie 'somatic tranformation' in GCTs. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

摘要

生殖细胞肿瘤(GCT)中出现的体细胞型恶性肿瘤(SM)是对全身治疗耐药的侵袭性肿瘤。大多数在化疗后的转移部位被诊断出来;然而,它们在原发性睾丸GCT中也有充分记录。从历史上看,SM被认为起源于畸胎瘤的成分,这些成分获得了与真正的体细胞对应物特征相同的分子改变。然而,最近的研究表明,SM通常缺乏在类似体细胞肿瘤中所见的标志性分子改变。此外,临床病理和分子数据表明,一部分SM可能来源于卵黄囊瘤(YST)而非畸胎瘤。在本研究中,我们通过比较微小RNA(miR)-371-373的表达和基因组甲基化谱,评估了GCT的传统组织学类型与SM之间的关系。通过逆转录定量聚合酶链反应(RT-qPCR)对96个样本(包括来自单个肿瘤的多个配对传统GCT-SM样本)进行miR-371-373表达评估,并使用经过临床验证的检测方法进行基因组DNA甲基化检测。miR-371-373在传统GCT中的表达高于SM(视为包含所有组织学亚型的单一类别)。然而,miR-371-373在SM中的表达是异质性的,肉瘤样YST(SYST)和腺性肿瘤中的水平显著高于其他SM。基因组DNA甲基化分析表明,SM(视为单一类别)并未形成一个独特的聚类。相反,它们分为多个聚类,这些聚类与组织学并不完全对应,并且常常包括传统GCT。全基因组甲基化评估显示,SM中高甲基化区域的丰度高于传统GCT。对从单个肿瘤中分离出的不符合SM大小标准的配对传统GCT和“体细胞型”成分进行分析,结果表明根据组织学进行了分离,这表明表观遗传过程在从传统GCT向“体细胞型”表型的转变中起作用。基因水平和通路水平分析确定丝裂原活化蛋白激酶/鼠肉瘤病毒癌基因(MAPK/RAS)信号传导、有丝分裂/增殖、向神经组织/神经外胚层的分化、上皮-间质转化和DNA修复是体细胞型组织学成分中关键的差异调节过程,提示了GCT中从传统向“体细胞”表型进展的机制。这些结果支持了一部分SM来源于YST的假说,并表明某些亚型(如SYST)可能代表“中间”表型。此外,对SM中差异甲基化启动子区域的分析确定了可能是GCT中“体细胞转化”基础的基因和生物学过程。© 2025作者。《病理学杂志》由约翰·威利父子有限公司代表大不列颠及爱尔兰病理学会出版。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f953/12056289/6be56295a828/PATH-266-160-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验